ProPhase Labs, Inc. (PRPH)
USD 0.31
(16.04%)
USD 0.31
(16.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 37.85 Million USD | -19.56% |
| 2022 | 47.05 Million USD | 104.49% |
| 2021 | 23.01 Million USD | 167.87% |
| 2020 | 8.59 Million USD | 46.75% |
| 2019 | 5.85 Million USD | -8.75% |
| 2018 | 6.41 Million USD | 8.03% |
| 2017 | 5.93 Million USD | -53.32% |
| 2016 | 12.72 Million USD | -19.29% |
| 2015 | 15.76 Million USD | -14.48% |
| 2014 | 18.43 Million USD | 13.38% |
| 2013 | 16.25 Million USD | -0.73% |
| 2012 | 16.37 Million USD | 16.79% |
| 2011 | 14.02 Million USD | 12.85% |
| 2010 | 12.42 Million USD | -19.87% |
| 2009 | 15.5 Million USD | -14.55% |
| 2008 | 18.14 Million USD | -29.91% |
| 2007 | 25.88 Million USD | 2.43% |
| 2006 | 25.27 Million USD | 1.67% |
| 2005 | 24.85 Million USD | 23.1% |
| 2004 | 20.19 Million USD | 4.21% |
| 2003 | 19.37 Million USD | 10.74% |
| 2002 | 17.49 Million USD | 13.02% |
| 2001 | 15.48 Million USD | -20.26% |
| 2000 | 19.41 Million USD | -19.44% |
| 1999 | 24.1 Million USD | 50.63% |
| 1998 | 16 Million USD | 17.65% |
| 1997 | 13.6 Million USD | 806.67% |
| 1996 | 1.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.35 Million USD | -6.54% |
| 2024 Q1 | 7.86 Million USD | -5.2% |
| 2023 Q1 | 9.64 Million USD | -41.09% |
| 2023 Q4 | 8.29 Million USD | -5.78% |
| 2023 FY | 37.85 Million USD | -19.56% |
| 2023 Q3 | 8.8 Million USD | -20.72% |
| 2023 Q2 | 11.1 Million USD | 15.15% |
| 2022 FY | 47.05 Million USD | 104.49% |
| 2022 Q4 | 16.37 Million USD | 63.4% |
| 2022 Q3 | 10.02 Million USD | 23.2% |
| 2022 Q2 | 8.13 Million USD | -35.1% |
| 2022 Q1 | 12.53 Million USD | 609.17% |
| 2021 Q4 | 1.76 Million USD | -76.82% |
| 2021 FY | 23.01 Million USD | 167.87% |
| 2021 Q2 | 5.91 Million USD | -23.23% |
| 2021 Q1 | 7.7 Million USD | 69.92% |
| 2021 Q3 | 7.62 Million USD | 28.87% |
| 2020 Q4 | 4.53 Million USD | 181.85% |
| 2020 Q1 | 1.22 Million USD | -16.3% |
| 2020 Q3 | 1.6 Million USD | 31.89% |
| 2020 Q2 | 1.22 Million USD | -0.57% |
| 2020 FY | 8.59 Million USD | 46.75% |
| 2019 Q4 | 1.46 Million USD | 13.2% |
| 2019 FY | 5.85 Million USD | -8.75% |
| 2019 Q3 | 1.29 Million USD | -15.3% |
| 2019 Q2 | 1.52 Million USD | -2.24% |
| 2019 Q1 | 1.56 Million USD | -10.48% |
| 2018 Q2 | 1.52 Million USD | 2.98% |
| 2018 FY | 6.41 Million USD | 8.03% |
| 2018 Q1 | 1.47 Million USD | -8.99% |
| 2018 Q3 | 1.66 Million USD | 9.59% |
| 2018 Q4 | 1.74 Million USD | 4.74% |
| 2017 Q3 | 1.33 Million USD | -23.81% |
| 2017 Q2 | 1.75 Million USD | 42.47% |
| 2017 Q4 | 1.62 Million USD | 21.74% |
| 2017 Q1 | 1.22 Million USD | -71.84% |
| 2017 FY | 5.93 Million USD | -53.32% |
| 2016 Q3 | 1.93 Million USD | -12.05% |
| 2016 Q2 | 2.2 Million USD | -47.9% |
| 2016 Q4 | 4.36 Million USD | 125.53% |
| 2016 Q1 | 4.22 Million USD | -29.98% |
| 2016 FY | 12.72 Million USD | -19.29% |
| 2015 Q4 | 6.03 Million USD | 185.02% |
| 2015 Q3 | 2.11 Million USD | -17.76% |
| 2015 Q1 | 5.04 Million USD | -23.28% |
| 2015 FY | 15.76 Million USD | -14.48% |
| 2015 Q2 | 2.57 Million USD | -48.96% |
| 2014 FY | 18.43 Million USD | 13.38% |
| 2014 Q1 | 4.78 Million USD | -19.98% |
| 2014 Q2 | 3.92 Million USD | -17.84% |
| 2014 Q3 | 3.14 Million USD | -19.88% |
| 2014 Q4 | 6.57 Million USD | 108.74% |
| 2013 Q3 | 2.58 Million USD | -2.53% |
| 2013 Q2 | 2.64 Million USD | -47.55% |
| 2013 Q1 | 5.04 Million USD | -19.35% |
| 2013 FY | 16.25 Million USD | -0.73% |
| 2013 Q4 | 5.97 Million USD | 131.54% |
| 2012 Q3 | 2.32 Million USD | -15.63% |
| 2012 Q1 | 5.03 Million USD | -24.17% |
| 2012 Q4 | 6.26 Million USD | 169.13% |
| 2012 Q2 | 2.75 Million USD | -45.19% |
| 2012 FY | 16.37 Million USD | 16.79% |
| 2011 Q3 | 2.49 Million USD | 32.52% |
| 2011 Q1 | 3.01 Million USD | -36.6% |
| 2011 Q2 | 1.87 Million USD | -37.76% |
| 2011 FY | 14.02 Million USD | 12.85% |
| 2011 Q4 | 6.63 Million USD | 166.39% |
| 2010 Q1 | 2.23 Million USD | -38.0% |
| 2010 Q3 | 2.67 Million USD | -2.69% |
| 2010 FY | 12.42 Million USD | -19.87% |
| 2010 Q4 | 4.76 Million USD | 78.02% |
| 2010 Q2 | 2.74 Million USD | 23.05% |
| 2009 Q2 | 4.92 Million USD | 7.85% |
| 2009 FY | 15.5 Million USD | -14.55% |
| 2009 Q1 | 4.56 Million USD | -6.18% |
| 2009 Q4 | 3.6 Million USD | 49.01% |
| 2009 Q3 | 2.41 Million USD | -50.86% |
| 2008 Q4 | 4.86 Million USD | 48.8% |
| 2008 Q3 | 3.26 Million USD | -15.35% |
| 2008 Q1 | 6.15 Million USD | -13.19% |
| 2008 Q2 | 3.86 Million USD | -37.23% |
| 2008 FY | 18.14 Million USD | -29.91% |
| 2007 Q3 | 5.78 Million USD | -2.36% |
| 2007 FY | 25.88 Million USD | 2.43% |
| 2007 Q1 | 7.09 Million USD | -10.58% |
| 2007 Q2 | 5.92 Million USD | -16.6% |
| 2007 Q4 | 7.08 Million USD | 22.58% |
| 2006 Q3 | 5.36 Million USD | 6.62% |
| 2006 FY | 25.27 Million USD | 1.67% |
| 2006 Q4 | 7.93 Million USD | 47.82% |
| 2006 Q2 | 5.03 Million USD | -27.27% |
| 2006 Q1 | 6.92 Million USD | -20.24% |
| 2005 Q1 | 5.89 Million USD | -19.25% |
| 2005 Q2 | 4.89 Million USD | -17.02% |
| 2005 FY | 24.85 Million USD | 23.1% |
| 2005 Q3 | 5.38 Million USD | 9.94% |
| 2005 Q4 | 8.68 Million USD | 61.37% |
| 2004 Q3 | 3.85 Million USD | 4.53% |
| 2004 Q1 | 5.32 Million USD | -18.61% |
| 2004 Q2 | 3.68 Million USD | -30.66% |
| 2004 Q4 | 7.3 Million USD | 89.39% |
| 2004 FY | 20.19 Million USD | 4.21% |
| 2003 Q4 | 6.53 Million USD | 49.5% |
| 2003 Q2 | 3.84 Million USD | -16.6% |
| 2003 Q3 | 4.37 Million USD | 13.58% |
| 2003 FY | 19.37 Million USD | 10.74% |
| 2003 Q1 | 4.61 Million USD | -12.21% |
| 2002 Q2 | 3.59 Million USD | -22.78% |
| 2002 Q4 | 5.25 Million USD | 32.17% |
| 2002 Q3 | 3.97 Million USD | 10.55% |
| 2002 Q1 | 4.66 Million USD | 5.95% |
| 2002 FY | 17.49 Million USD | 13.02% |
| 2001 Q3 | 3.75 Million USD | 0.05% |
| 2001 FY | 15.48 Million USD | -20.26% |
| 2001 Q1 | 3.57 Million USD | -36.65% |
| 2001 Q2 | 3.75 Million USD | 5.0% |
| 2001 Q4 | 4.39 Million USD | 17.15% |
| 2000 Q4 | 5.64 Million USD | 114.24% |
| 2000 FY | 19.41 Million USD | -19.44% |
| 2000 Q3 | 2.63 Million USD | -2.5% |
| 2000 Q2 | 2.7 Million USD | -67.99% |
| 2000 Q1 | 8.43 Million USD | -18.86% |
| 1999 FY | 24.1 Million USD | 50.63% |
| 1999 Q1 | 7.5 Million USD | -9.64% |
| 1999 Q2 | 3.4 Million USD | -54.67% |
| 1999 Q3 | 2.9 Million USD | -14.71% |
| 1999 Q4 | 10.4 Million USD | 258.62% |
| 1998 Q4 | 8.3 Million USD | 176.67% |
| 1998 Q1 | 3.4 Million USD | -32.0% |
| 1998 Q3 | 3 Million USD | 130.77% |
| 1998 FY | 16 Million USD | 17.65% |
| 1998 Q2 | 1.3 Million USD | -61.76% |
| 1997 Q1 | 4.4 Million USD | 443.21% |
| 1997 Q4 | 5 Million USD | 66.67% |
| 1997 Q2 | 1.2 Million USD | -72.73% |
| 1997 FY | 13.6 Million USD | 806.67% |
| 1997 Q3 | 3 Million USD | 150.0% |
| 1996 FY | 1.5 Million USD | 0.0% |
| 1996 Q4 | 810 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -358.652% |
| Alpha Teknova, Inc. | 45.85 Million USD | 17.46% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 80.686% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 15.611% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 76.225% |
| Cosmos Health Inc. | 26.18 Million USD | -44.579% |
| Journey Medical Corporation | 54.59 Million USD | 30.666% |
| Embecta Corp. | 528.4 Million USD | 92.836% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 86.079% |
| Dynavax Technologies Corporation | 219.14 Million USD | 82.727% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 93.584% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 88.402% |
| PainReform Ltd. | 9.58 Million USD | -294.95% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -188.408% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -188.408% |
| SCYNEXIS, Inc. | 51.84 Million USD | 26.994% |
| Safety Shot Inc | 12.1 Million USD | -212.576% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1133.29% |
| Procaps Group, S.A. | 199.47 Million USD | 81.024% |
| Theratechnologies Inc. | 72.75 Million USD | 47.974% |
| Harrow Health, Inc. | 89.97 Million USD | 57.93% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -300.72% |
| Biofrontera Inc. | 39.95 Million USD | 5.273% |
| DURECT Corporation | 43.71 Million USD | 13.412% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 92.845% |
| Cronos Group Inc. | 96.7 Million USD | 60.86% |
| OptiNose, Inc. | 85.1 Million USD | 55.522% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 83.693% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 3.323% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 495.9% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 87.95% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -288.99% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 12.055% |
| Radius Health, Inc. | 265.92 Million USD | 85.766% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -173.459% |
| Phibro Animal Health Corporation | 260.29 Million USD | 85.458% |
| Procaps Group S.A. | 187.24 Million USD | 79.785% |
| Alvotech | 285.43 Million USD | 86.739% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -285.262% |
| Viatris Inc. | 5.96 Billion USD | 99.366% |
| Rockwell Medical, Inc. | 15.37 Million USD | -146.208% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 36.745% |
| SIGA Technologies, Inc. | 22.04 Million USD | -71.719% |
| Tilray Brands, Inc. | 251.35 Million USD | 84.941% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 22.811% |
| Shineco, Inc. | 17.94 Million USD | -110.898% |
| PetIQ, Inc. | 192.72 Million USD | 80.36% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -848.401% |
| Incannex Healthcare Limited | 30.05 Million USD | -25.951% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.629% |
| Alimera Sciences, Inc. | 62.64 Million USD | 39.573% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -4864.249% |
| Assertio Holdings, Inc. | 368.58 Million USD | 89.73% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -543.132% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -112.55% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -78.809% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -79.887% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 77.055% |
| Hempacco Co., Inc. | 7.59 Million USD | -398.285% |
| Talphera, Inc. | 11.99 Million USD | -215.591% |
| Alvotech | 285.43 Million USD | 86.739% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 73.1% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 89.025% |
| Currenc Group, Inc. | 24 Million USD | -57.703% |
| Kamada Ltd. | 45.42 Million USD | 16.673% |
| Indivior PLC | 911 Million USD | 95.845% |
| Evoke Pharma, Inc. | 12.4 Million USD | -205.021% |
| Flora Growth Corp. | 10.57 Million USD | -257.803% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -79.887% |
| Evolus, Inc. | 189.75 Million USD | 80.053% |
| HUTCHMED (China) Limited | 436.23 Million USD | 91.323% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 75.442% |
| Akanda Corp. | 3.48 Million USD | -986.606% |